Xeris Biopharma (NASDAQ:XERS) Raised to Strong-Buy at Wall Street Zen

Xeris Biopharma (NASDAQ:XERS) was upgraded by investment analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a report released on Saturday.

A number of other equities analysts have also weighed in on the stock. Oppenheimer restated an “outperform” rating and issued a $18.00 price objective on shares of Xeris Biopharma in a report on Friday, November 7th. Barclays started coverage on Xeris Biopharma in a report on Monday, December 8th. They issued an “overweight” rating and a $9.00 target price for the company. Weiss Ratings upgraded Xeris Biopharma from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Xeris Biopharma in a report on Monday, March 2nd. Finally, Piper Sandler increased their price objective on Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Four investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $10.80.

Xeris Biopharma Stock Down 3.8%

NASDAQ:XERS opened at $5.81 on Friday. The company has a debt-to-equity ratio of 16.10, a quick ratio of 1.57 and a current ratio of 2.19. The firm has a market cap of $1.00 billion, a P/E ratio of -580.42 and a beta of 0.61. Xeris Biopharma has a fifty-two week low of $3.81 and a fifty-two week high of $10.08. The firm has a 50-day simple moving average of $7.10 and a two-hundred day simple moving average of $7.59.

Xeris Biopharma (NASDAQ:XERS) last issued its earnings results on Monday, March 2nd. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.03. Xeris Biopharma had a net margin of 0.19% and a negative return on equity of 5.33%. The firm had revenue of $85.81 million for the quarter, compared to the consensus estimate of $86.00 million. Analysts predict that Xeris Biopharma will post -0.41 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Xeris Biopharma news, insider Beth Hecht sold 16,667 shares of Xeris Biopharma stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $6.25, for a total value of $104,168.75. Following the completion of the sale, the insider owned 1,226,507 shares of the company’s stock, valued at approximately $7,665,668.75. The trade was a 1.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Barbara-Jean A. Bormann-Kennedy sold 15,000 shares of the business’s stock in a transaction on Friday, December 12th. The shares were sold at an average price of $7.09, for a total transaction of $106,350.00. Following the sale, the director owned 142,500 shares of the company’s stock, valued at approximately $1,010,325. This represents a 9.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 240,308 shares of company stock valued at $1,732,453 in the last ninety days. Corporate insiders own 4.56% of the company’s stock.

Institutional Trading of Xeris Biopharma

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in Xeris Biopharma by 13.8% in the fourth quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock valued at $87,815,000 after acquiring an additional 1,358,760 shares during the period. Geode Capital Management LLC grew its stake in shares of Xeris Biopharma by 3.3% during the 4th quarter. Geode Capital Management LLC now owns 4,275,989 shares of the company’s stock valued at $33,571,000 after purchasing an additional 135,815 shares during the period. State Street Corp increased its position in shares of Xeris Biopharma by 10.1% during the 4th quarter. State Street Corp now owns 4,116,924 shares of the company’s stock valued at $32,318,000 after purchasing an additional 378,595 shares during the last quarter. Qube Research & Technologies Ltd increased its position in shares of Xeris Biopharma by 6.0% during the 3rd quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company’s stock valued at $26,657,000 after purchasing an additional 185,063 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Xeris Biopharma by 75.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after purchasing an additional 1,199,435 shares during the period. Hedge funds and other institutional investors own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.